Downloads
-
Strategic Synthesis Of ASGCT And ASCO 2026
6/10/2026
The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.
-
Hybridoma Services
6/5/2026
Curia’s in vivo Discovery Immunology team offers high-performance hybridoma-based technologies to help clients discover great antibodies that make a difference.
-
Phage And Yeast Display
6/5/2026
Curia offers phage and eukaryotic-based yeast display platforms for in vitro discovery and engineering of potent antibody candidates for therapeutic or diagnostic use. High-affinity functional antibodies are routinely selected against a wide range of conventional or challenging targets (e.g. GPCRs) using customized or in-licensed state-of-the-art libraries.
-
Recombinant Antibody Production
6/5/2026
Curia has extensive experience with constructing and producing antibodies in our mammalian platforms.
-
CHO Transient Production (TunaCHO® Process)
6/5/2026
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.
-
HEK293 Transient Production (Tuna293® Process)
6/5/2026
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.
-
Mammalian High-Throughput Production
6/5/2026
The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.
-
Bacterial Expression
6/5/2026
E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.
-
Antibody Developability Analysis
6/5/2026
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
Biological And Functional Assays
6/5/2026
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns